Today, I would like to have an open and honest conversation with our shareholders, reflecting on Fosun’s journey in 2025, sharing our thoughts, and outlining where we are heading next.

(26 March 2026) The world’s leading index company MSCI recently released its latest annual Environmental, Social and Governance (“ESG”) ratings. The results, announced in March 2026, are based on MSCI’s latest rating model (version 5.0). Thanks to its outstanding performance across all ESG aspects, Fosun International Limited (HKEX stock code: 00656, hereinafter referred to as “Fosun International”, “Fosun”, or the “Group”) saw its rating rise from AA to AAA. This marks Fosun International’s first time achieving the highest MSCI ESG rating since first earning an AA rating in 2021, following five years of sustained efforts, demonstrating Fosun’s achievements and global leadership in sustainability.

SHANGHAI, March 13, 2026 -- Fosun International Limited ("Fosun International", stock code: 00656.HK) and HSBC Bank (China) Company Limited ("HSBC China") renewed a strategic cooperation agreement (the "Agreement") today to provide strong support for Fosun International and its subsidiaries ("Fosun") in further enhancing global operation and investment capabilities, advancing future growth strategies, and strengthening financial resources.

On 23 February 2026, The Hong Kong Management Association (HKMA) held the 2025 HKMA Best Annual Reports Awards presentation ceremony in Hong Kong. Fosun International received the “Certificate of Excellence in Environmental, Social and Governance Reporting”, underscoring the company’s outstanding performance in ESG strategy, environmental protection, social responsibility, corporate governance and information disclosure, and its continued recognition by industry authorities.

TOKYO and SHANGHAI, Feb. 5, 2026 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly^® in the EU) in Japan.

China Daily, China’s national English-language newspaper, recently released a video report titled “Shared Journey: From investment to partnership - How a Chinese Company Has Taken Root in Europe”. As part of China Daily’s special report commemorating the 50th anniversary of diplomatic relations between China and the European Union, the video explores practices and experiences of Chinese companies in their long-term development in Europe. Fosun, one of the few Chinese private enterprises that has consistently and deeply cultivated overseas markets, was featured in the report.

Recently, the world’s leading index company, FTSE Russell, announced Fosun International Limited (HKEX stock code: 00656) (“Fosun International”) Environmental, Social and Governance (ESG) rating, with the latest score rising to 4.2. At the same time, Fosun International announced it has been included in the FTSE4Good Index Series for the fifth consecutive time.

On 18 January, the 9th Shanghai Forum Themed Zhejiang Entrepreneurs in the World & 2025 Annual Meeting of ZCCS (Zhejiang Chamber of Commerce in Shanghai) took place at the Shanghai International Convention Center. The forum, themed around “Surging Forward”, highlighted the resilience, innovation, and ambition of Zhejiang entrepreneurs amid China’s economic tides, bringing together academics, experts, technology pioneers, and renowned entrepreneurs to discuss future development. Guo Guangchang, Chairman of Fosun International, delivered a keynote speech, sharing his insights on macroeconomic landscape, innovation in private enterprises, the vast Chinese market, and globalization opportunities.

January 14, 2026 – At the 2026 J.P. Morgan Healthcare Conference, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into an exclusive global license agreement with U-mab Biopharma (Lianyungang) Co.,Ltd. ("U-mab"), a company focused on developing innovative therapies for oncology and inflammatory diseases. Under the agreement, Henlius has secured rights to a monoclonal antibody (mAb) targeting Interleukin-1 Receptor Accessory Protein (IL-1RAP) with best-in-class(BIC) potential. Building upon its core expertise in tumor immunotherapy, this partnership marks an expansion of Henlius’ efforts into immune-inflammatory diseases.